Cassava Sciences, Inc. has appointed Dr. Joseph Hulihan as their new Chief Medical Officer. Dr. Hulihan will focus on the clinical development of simufilam, a treatment candidate for Tuberous Sclerosis Complex-related epilepsy, dedicating about half of his professional time to the role. A clinical study for simufilam is expected to begin in the first half of 2026. Dr. Hulihan brings over 25 years of experience in the development of therapeutics for neurological disorders.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.